Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis
Autore:
Moreland, LW; Cohen, SB; Baumgartner, SW; Tindall, EA; Bulpitt, K; Martin, R; Weinblatt, M; Taborn, J; Weaver, A; Burge, DJ; Schiff, MH;
Indirizzi:
Univ Alabama, Div Clin Immunol & Rheumatol, Arthrit Clin Intervent Program, Birmingham, AL 35294 USA Univ Alabama Birmingham AL USA 35294 nt Program, Birmingham, AL 35294 USA Metroplex Clin Res Ctr, Dallas, TX USA Metroplex Clin Res Ctr Dallas TX USA roplex Clin Res Ctr, Dallas, TX USA Physicians Clin Spokane, Spokane, WA USA Physicians Clin Spokane Spokane WA USA ans Clin Spokane, Spokane, WA USA Portland Med Associates, Portland, OR USA Portland Med Associates Portland OR USA Med Associates, Portland, OR USA Univ Calif Los Angeles, Los Angeles, CA USA Univ Calif Los Angeles Los Angeles CA USA s Angeles, Los Angeles, CA USA Brigham & Womens Hosp, Boston, MA 02115 USA Brigham & Womens Hosp Boston MA USA 02115 mens Hosp, Boston, MA 02115 USA Midwest Arthrit Ctr, Kalamazoo, MI USA Midwest Arthrit Ctr Kalamazoo MI USA west Arthrit Ctr, Kalamazoo, MI USA Arthrit Ctr Nebraska, Lincoln, NE USA Arthrit Ctr Nebraska Lincoln NE USA rthrit Ctr Nebraska, Lincoln, NE USA Immunex Corp, Seattle, WA USA Immunex Corp Seattle WA USAImmunex Corp, Seattle, WA USA Denver Arthrit Clin, Denver, CO USA Denver Arthrit Clin Denver CO USADenver Arthrit Clin, Denver, CO USA
Titolo Testata:
JOURNAL OF RHEUMATOLOGY
fascicolo: 6, volume: 28, anno: 2001,
pagine: 1238 - 1244
SICI:
0315-162X(200106)28:6<1238:LSAEOE>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; MYELOGENOUS LEUKEMIA; FUSION PROTEIN; CYTOKINES; RECEPTOR; MICE; INDUCTION; SYNERGY; MURINE;
Keywords:
rheumatoid arthritis; tumor necrosis factor receptor; etanercept;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Moreland, LW Univ Alabama, Div Clin Immunol & Rheumatol, Arthrit Clin Intervent Program, 1717 6th Ave S,Room 068, Birmingham, AL 35294 USA Univ Alabama 1717 6th Ave S,Room 068 Birmingham AL USA 35294
Citazione:
L.W. Moreland et al., "Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis", J RHEUMATOL, 28(6), 2001, pp. 1238-1244

Abstract

Objective. Patients with rheumatoid arthritis (RA) treated with etanercept(Enbrel((R))) in controlled studies of 3 to 6 months' duration had rapid and sustained improvement of their disease, with minimal safety issues. In this study, we examine safety and clinical benefit after longer term treatment with etanercept. Methods. All adult patients with RA with a previously inadequate response to one or more disease modifying antirheumatic drugs, and who received at least one dose of etanercept as monotherapy in controlled or open label clinical trials were evaluated for safety and clinical benefit. Adverse event rates were compared as was evidence of continued benefit over time. Results. Etanercept continued to be safe and well tolerated in 628 adult patients treated for a median of 25 mo (maximum 43 mo; 1109 patient-years). Nine percent of patients withdrew due to lack of efficacy and 7% due to adverse events. Most adverse events were mild, and no statistically significant increases in frequency of events were seen when patients received etanercept over longer periods of time. Clinical benefit was maintained with longterm therapy. A 100% improvement in individual disease activity measures wasachieved by 17% to 28% of the patients. Fifty-five percent of patients whowere taking corticosteroids (mean dose at baseline 6.6 mg/day) decreased or discontinued corticosteroid therapy while maintaining control of their arthritis symptoms. Conclusion. Etanercept continued to be safe and well tolerated, and its clinical benefit was sustained for a median of 25 mo and for as long as 43 moin patients with RA.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/07/20 alle ore 01:46:54